OTHMAN ALAMI: Open Payments
NPI 1336264241 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$170 in 7 payments from 5 companies in 2025. Trend: 2023 $379 · 2024 $319 · 2025 $170
Food & beverage: $170
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
| Janssen Pharmaceuticals, Inc | 1 | $30 |
| E.R. Squibb & Sons, L.L.C. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
Products named: CAPLYTA, SPRAVATO, ABILIFY ASIMTUFII, COBENFY, ABILIFY MAINTENA, UZEDY.
Industry payments across CA — which companies pay providers there.
